What were the main drivers of Bristol-Myers Squibb's sales growth in 2004?

The primary drivers of sales growth in 2004 were the favorable impact of foreign exchange rates and strong performance from key products, particularly PLAVIX, which saw a 35% increase in sales. Newer product launches like ABILIFY, REYATAZ, and ERBITUX also contributed positively, helping to offset declines from older products that faced exclusivity losses.

What is the company's strategy for managing product exclusivity losses?

Bristol-Myers Squibb is strategically shifting its focus to ten critical disease areas, investing heavily in R&D to develop innovative treatments. This involves rebalancing drug discovery and development to support its late-stage pipeline, pursuing in-licensing opportunities, and preparing for new product launches. The company is also actively managing its portfolio through divestitures of non-core businesses.

What were the key financial impacts of the SEC settlement and restatements?

In August 2004, the company settled with the SEC concerning wholesaler inventory and accounting matters, agreeing to a $150 million shareholder fund and a civil penalty. The company also underwent further restatements of its financial statements for prior years due to identified errors in internal controls. While these events indicate past accounting control weaknesses, the company asserts it has taken significant steps to remediate these issues and strengthen its internal controls.

What is the company's outlook for future financial performance?

The company anticipates substantial revenue losses in the coming years due to continued patent expirations and generic competition for key products like PRAVACHOL and PARAPLATIN. However, management expects earnings growth to resume in 2007, driven by the anticipated growth of in-line products, recent launches, and potential new product approvals. This outlook is contingent on successful product development and market penetration, as well as the effective management of costs and litigation outcomes.

BRISTOL MYERS SQUIBB CO 10-K FY2004 Annual Report

Summary

Bristol-Myers Squibb (BMY) filed its 2004 10-K report on March 3, 2005, detailing its financial performance and operations. The company reported net sales of $19.4 billion, a 4% increase year-over-year, driven by favorable foreign exchange rates and strong performance from key products like PLAVIX, which saw a 35% sales increase. However, the company also experienced a 7% decline in PRAVACHOL sales due to increased generic competition and exclusivity losses. The company continued its strategic focus on ten critical disease areas, investing $2.5 billion in R&D, a 10% increase from the prior year. New product introductions such as ABILIFY, REYATAZ, and ERBITUX are key to offsetting declines from older, off-patent brands. Management is also actively managing its portfolio through divestitures, including the planned sale of its Oncology Therapeutics Network (OTN) business and its U.S. and Canadian Consumer Medicines businesses. A significant point of note is the ongoing impact of past accounting and inventory issues, with the company settling with the SEC in August 2004 and undergoing further restatements due to identified errors. Investors should note the impact of these restatements and the ongoing legal proceedings on the company's financial results and future outlook.

Key Highlights

1Net sales reached $19.4 billion in 2004, a 4% increase driven by favorable foreign exchange, with international sales growing 10%.
2PLAVIX was a major growth driver, with sales increasing 35% to $3.3 billion, while PRAVACHOL sales declined 7% to $2.6 billion.
3Research and development spending increased 10% to $2.5 billion, reflecting a strategic focus on ten critical disease areas and new product development.
4The company announced plans to divest its Oncology Therapeutics Network (OTN) business and its U.S. and Canadian Consumer Medicines businesses.
5Bristol-Myers Squibb settled with the SEC in August 2004 regarding wholesaler inventory and accounting matters, leading to a $150 million shareholder fund.
6The company restated its financial statements for 2001 and 2002 in 2004 to correct additional errors identified during its ongoing efforts to enhance internal controls.
7Despite revenue challenges from patent expirations, the company expressed confidence in future earnings growth resuming in 2007, supported by new product launches and cost rationalization.

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2004

Summary

Key Highlights

Frequently Asked Questions